Menu
  • Join
  • Login
  • Contact
 

Search abstracts


EVALUATION OF THE EFFICACY AND SAFETY FOR CHRONIC HEPATITIS C TREATED WITH ELBASVIR/GRAZOPREVIR

  • At: 2019 FIP Congress in AbuDhabi (United Arab Emirates)
  • Type: Poster
  • By: TSAI, Tzu-Cheng (Chang Gung Memorial Hospital, Pharmacy, China Taiwan)
  • Co-author(s): Tzu-Cheng Tsai: Pharmacy, Chang Gung Memorial Hospital, China Taiwan
    Hui-Yu Chen: Pharmacy, Chang Gung Memorial Hospital, China Taiwan
    Shin-Tarng Deng: Pharmacy, Chang Gung Memorial Hospital, China Taiwan
    Chao-Wei Hsu: Gastroenterology and Hepatology, Chang Gung Memorial Hospital, China Taiwan
  • Abstract:

    Background

    Elbasvir/grazoprevir (EBR/GZR) is a new generation, fixed-dose, combination antiviral drug used in chronic hepatitis C virus (HCV) genotype (GT) 1 or 4 infection.

    Methods

    This is a retrospective observational study. Patients were recruited who had received EBR/GZR for chronic HCV GT 1 between June 2017 and April 2018. Patients’ age, sex,

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses